PAT-DX1 GMP specification testing update
Released
Released
Announcement PDF
ASX & Media Release
PAT-DX1 GMP specification testing update
Melbourne, Australia; 20 September 2024: Patrys Limited (ASX: PAB, “Patrys” or the “Company”), a
therapeutic antibody development company, provides the following update regarding the recently
completed GMP manufacturing run of PAT-DX1.
Patrys’ Contract Development Manufacturing Organization (CDMO) has advised the Company that the
Quality Assurance and Quality Control approvals for the revised specification testing protocols are
pending, and accordingly the final product testing is yet to be completed. Accordingly, the Company
has been advised that specification testing for the drug substance produced in the recent
manufacturing run of PAT-DX1 is now expected to be complete in the first half of October 2024.
As previously noted this specification testing must be successfully completed for the drug material to
be released for use in clinical trials, and delays with specification testing and drug release directly
impact on the commencement of clinical development activities for PAT-DX1. The Company will advise
if there are any further amendments or developments in relation to this revised timeline.
-Ends-
This announcement is authorised for release by the Board of Directors of Patrys Limited.
For further information, please contact:
General enquiries
James Campbell
Chief Executive Officer
P: +61 3 96703273
info@patrys.com
Media enquiries:
Haley Chartres
H^CK
P: +61 423 139 163
haley@hck.digital
1
Registered Office Address
Level 4, 100 Albert Road
South Melbourne VIC 3205
About Patrys Limited
Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of its deoxymab
platform of cell-penetrating antibodies as therapies for a range of different cancers. More information
can be found at www.patrys.com.
About Patrys’ deoxymab 3E10 platform: Patrys’ deoxymab platform is based on the deoxymab 3E10
antibody that was first identified as an autoantibody in a mouse model of the human disease systemic
lupus erythematosus (SLE). While most antibodies bind to cell surface markers, deoxymab 3E10
penetrates into the cell nuclei and binds directly to DNA where it inhibits DNA repair processes. Cancer
cells often have high levels of mutations and underlying deficiencies in the DNA repair mechanisms.
For these reasons, the additional inhibition of the DNA repair processes by deoxymab 3E10 can kill
cancer cells, but appears to have little impact on normal cells. As a single agent, deoxymab 3E10 has
been shown to significantly enhance the efficacy of both chemo- and radiotherapies. Further,
deoxymab 3E10 can be conjugated to nanoparticles to target delivery of chemotherapeutics and
imaging agents to tumours.
Patrys has developed two humanised forms of deoxymab 3E10, both which have improved activity
over the original deoxymab 3E10 antibody. PAT-DX1 is a dimer (two joined subunits) of the short chain
from the binding domain of deoxymab 3E10, while PAT-DX3 is a full-sized IgG antibody. In a range of
pre-clinical studies, PAT-DX1 has shown significant ability to kill cancer cells in cell models, human
tumour explants, xenograft and orthotopic models. PAT-DX1 has been shown to cross the blood brain
barrier, reduce tumour size, and increase survival in multiple animal models of brain cancer, other
cancers, and cancer metastases. PAT-DX1 is tumour-agnostic, meaning that it can target many
different tumour types in the body, regardless of specific tumour antigens. Patrys believes that PATDX1 may have application across a wide range of cancers including gliomas, melanomas, prostate,
breast, pancreatic and ovarian cancers.
Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of
anti-cancer drugs specifically to tumours. This allows specific delivery of cancer drugs to multiple types
of cancer while having minimal impact on normal, healthy cells.
Patrys’ rights to deoxymab 3E10 are part of a worldwide license to develop and commercialise a
portfolio of novel anti-DNA antibodies and antibody fragments, variants and conjugates discovered at
Yale University as anti-cancer and diagnostic agents. Six patents covering the unconjugated form of
deoxymab 3E10 (and derivatives thereof) have already been granted (Europe, Japan, China, and 3 in
the USA), and five patents covering nanoparticle conjugation has been granted (Australia, Canada,
China, India and the USA).
2
Share your feedback
Discover